Top Markets
Coin of the day
Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc.

Qualigen Therapeutics, Inc.

QLGN
Rang in Aktien #35381
Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing... Qualigen Therapeutics, Inc. is a biotechnology enterprise focused on advancing groundbreaking treatments for both cancer and infectious diseases. In addition to its developmental pipeline, the company offers FastPack, an efficient system designed for swift diagnostic testing. Its therapeutic candidates currently undergoing development include QN-302, an investigational compound targeting pancreatic ductal adenocarcinoma; QN-247, a DNA-coated gold nanoparticle formulated to combat various types of cancer; and RAS-F, a small-molecule inhibitor designed to block RAS oncogene protein-protein interactions, thereby impeding RAS mutations and suppressing tumor growth. The company is also progressing with the STARS blood cleansing system, an innovative DNA/RNA-based device engineered to purify a patient's bloodstream by eliminating tumor-derived substances and viruses. Founded in 1996, Qualigen Therapeutics, Inc. is headquartered in Carlsbad, California.
Aktienkurs
$2.37
Zuletzt synchronisiert: 2025-12-15
Marktkapitalisierung
$3.99M
Veränderung (1 Tag)
-5.58%
Veränderung (1 Jahr)
24.74%
Land
US
Handel Qualigen Therapeutics, Inc. (QLGN)

Kategorie

Dividendenrendite-Verlauf für Qualigen Therapeutics, Inc. (QLGN)
Dividendenrendite (TTM) von Qualigen Therapeutics, Inc. (Aktienkürzel: QLGN) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Qualigen Therapeutics, Inc. (QLGN) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber